NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
Clinical Trials
14 trialsNCT03798626 2026-01-27
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04631744 2025-12-18
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Completed
NCT05052723 2025-11-19
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Phase 2 Completed
NCT04477512 2025-11-12
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
Phase 1 Completed
NCT01935934 2025-10-01
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03685448 2025-08-08
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03967522 2025-08-08
CABRAMET
Centre Leon Berard
Phase 2 Completed
NCT01979393 2025-08-01
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01441947 2025-05-25
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04804813 2025-04-11
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Takeda
Completed
NCT04316182 2025-03-30
ACTION
Fundacion Clinic per a la Recerca Biomédica
Phase 2 Completed